Literature DB >> 4850497

Amino acid metabolism in acute renal failure: influence of intravenous essential L-amino acid hyperalimentation therapy.

R M Abel, V E Shih, W M Abbott, C H Beck, J E Fischer.   

Abstract

A solution of 8 essential I-amino acids and hypertonic dextrose was administered to 5 patients in acute postoperative renal failure in a program of hyperalimentation designed to decrease the patient's catabolic state and to accrue certain metabolic benefits. A sixth patient receiving intravenous glucose alone served as a control. The pretreatment plasma concentrations of amino acids in all 6 patients did not differ significantly from normal; following intravenous essential amino acids at a dose of approximately 12.6 gm/24 hours, no significant elevations out of the normal range of these substances occurred. Since urinary excretion rates did not dramatically increase, urinary loss was excluded as a possible cause for the failure of increase of plasma concentrations. The results suggest that the administration of an intravenous solution of 1-amino acids and hypertonic dextrose is associated with rapid clearance from the blood of these substances and, with a failure of increased urinary excretion, indirect evidence of amino acid utilization for protein synthesis has been obtained. Histidine supplementation in patients with acute renal failure is probably unnecessary based on the lack of significant decreases in histidine concentrations in these patients.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4850497      PMCID: PMC1343671          DOI: 10.1097/00000658-197409000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  Improved survival from acute renal failure after treatment with intravenous essential L-amino acids and glucose. Results of a prospective, double-blind study.

Authors:  R M Abel; C H Beck; W M Abbott; J A Ryan; G O Barnett; J E Fischer
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

2.  Diagnosis.

Authors:  J W Dickey
Journal:  Am J Surg       Date:  1972-06       Impact factor: 2.565

3.  Treatment of acute renal insufficiency after aortoiliac surgery.

Authors:  W M Abbott; R M Abel; J E Fischer
Journal:  Arch Surg       Date:  1971-11

4.  Pulmonary embolism revisited.

Authors:  A R Cordell; G Podgorny; C Ferguson; A S Hudspeth; F R Johnston
Journal:  Ann Surg       Date:  1969-06       Impact factor: 12.969

5.  Individual plasma-free amino acids in uremics: effects of hemodialysis.

Authors:  M E Rubini; S Gordon
Journal:  Nephron       Date:  1968       Impact factor: 2.847

6.  Treatment of acute renal failure with intravenous administration of essential amino acids and glucose.

Authors:  R M Abel; C H Beck; W M Abbott; J A Ryan; G O Barnett; J E Fischer
Journal:  Surg Forum       Date:  1972

7.  Catheter complications in total parenteral nutrition. A prospective study of 200 consecutive patients.

Authors:  J A Ryan; R M Abel; W M Abbott; C C Hopkins; T M Chesney; R Colley; K Phillips; J E Fischer
Journal:  N Engl J Med       Date:  1974-04-04       Impact factor: 91.245

8.  Intravenous nutrition with amino acid solutions in patients with chronic uraemia.

Authors:  J Bergström; H Bucht; P Fürst; E Hultman; B Josephson; L O Norée; E Vinnars
Journal:  Acta Med Scand       Date:  1972-04

9.  Acute renal failure. Treatment without dialysis by total parenteral nutrition.

Authors:  R M Abel; W M Abbott; J E Fischer
Journal:  Arch Surg       Date:  1971-10

10.  Treatment of acute renal failure with intravenous essential L-amino acids.

Authors:  D W Wilmore; S J Dudrick
Journal:  Arch Surg       Date:  1969-11
View more
  2 in total

Review 1.  Nutrition support therapy in acute kidney injury: distinguishing dogma from good practice.

Authors:  Jane M Gervasio; Ann B Cotton
Journal:  Curr Gastroenterol Rep       Date:  2009-08

2.  Five-gene signature predicts acute kidney injury in early kidney transplant patients.

Authors:  Xia Zhai; Hongqiang Lou; Jing Hu
Journal:  Aging (Albany NY)       Date:  2022-03-23       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.